Your browser is no longer supported. Please, upgrade your browser.
Talis Biomedical Corporation
Index- P/E- EPS (ttm)- Insider Own1.20% Shs Outstand23.48M Perf Week7.75%
Market Cap293.28M Forward P/E- EPS next Y-1.52 Insider Trans- Shs Float7.96M Perf Month7.75%
Income- PEG- EPS next Q-0.91 Inst Own82.00% Short Float25.87% Perf Quarter-4.85%
Sales10.94M P/S26.81 EPS this Y-445.40% Inst Trans- Short Ratio11.57 Perf Half Y-
Book/sh15.18 P/B0.72 EPS next Y52.20% ROA- Target Price14.00 Perf Year-
Cash/sh13.03 P/C0.84 EPS next 5Y47.30% ROE- 52W Range9.43 - 33.90 Perf YTD-60.50%
Dividend- P/FCF- EPS past 5Y- ROI84.00% 52W High-67.61% Beta-
Dividend %- Quick Ratio8.40 Sales past 5Y- Gross Margin- 52W Low16.44% ATR0.81
Employees133 Current Ratio8.40 Sales Q/Q180.00% Oper. Margin- RSI (14)53.32 Volatility5.92% 8.41%
OptionableNo Debt/Eq0.00 EPS Q/Q-204.90% Profit Margin- Rel Volume0.86 Prev Close10.31
ShortableYes LT Debt/Eq0.00 EarningsMay 11 AMC Payout- Avg Volume177.84K Price10.98
Recom2.00 SMA206.06% SMA50-0.88% SMA200-17.19% Volume154,019 Change6.50%
Mar-09-21Initiated Piper Sandler Overweight $17
Mar-09-21Initiated JP Morgan Overweight $18
Mar-09-21Initiated BTIG Research Buy $18
Mar-09-21Initiated BofA Securities Neutral $14
May-12-21 08:00AM  
May-11-21 04:05PM  
May-04-21 08:00AM  
Apr-28-21 08:00AM  
Mar-18-21 08:00AM  
Mar-09-21 10:07AM  
Mar-08-21 08:00AM  
Feb-17-21 04:05PM  
Feb-12-21 05:05PM  
Feb-11-21 11:39PM  
Talis Biomedical Corporation operates as a molecular diagnostic company. It is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. The company is also developing Talis One assay kits for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B plus SARS-CoV-2. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Scott Randal W.DirectorMay 17Buy10.1111,000111,21020,000May 18 03:19 PM
Scott Randal W.DirectorMay 14Buy10.169,00091,4409,000May 18 03:19 PM
Ramakrishnan RameshSr. Vice President, R&DFeb 17Buy16.001,00016,0001,000Feb 19 06:16 PM
Posard Matthew L.DirectorFeb 17Buy16.0062,5001,000,00062,500Feb 19 06:13 PM
Moody John Roger JrChief Financial OfficerFeb 17Buy16.001,70027,2001,700Feb 19 06:01 PM
Liu DouglasSr. Vice President, OperationsFeb 17Buy16.004,00064,0004,000Feb 19 05:59 PM
Flick Karen E.Chief of Staff, Sr. VP, LegalFeb 17Buy16.002,00032,0002,000Feb 19 05:55 PM
Popovits Kimberly JDirectorFeb 17Buy16.005,30084,800215,090Feb 19 06:21 PM
Scott Randal W.DirectorFeb 17Buy16.00312,5005,000,000312,500Feb 19 06:18 PM
BAKER BROS. ADVISORS LPDirectorFeb 17Buy16.006,250,000100,000,0007,003,176Feb 19 06:17 PM